EOLS FY 2024 Earnings — Evolus, Inc. Revenue & Financial Results | Market Cap Arena

EOLSEvolus, Inc.

$353M

FY 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$266M+31.8% YoY

Gross Profit

$182M68.5% margin

Operating Income

-$34M-12.9% margin

Net Income

-$50M-18.9% margin

EPS (Diluted)

$-0.81

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$19M

Stock-Based Comp.

$22M

Balance Sheet

Total Assets

$233M

Total Liabilities

$227M

Stockholders' Equity

$6M

Cash & Equivalents

$87M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$266M	$202M	+31.8%
Gross Profit	$182M	$141M	+29.7%
Operating Income	-$34M	-$49M	+30.1%
Net Income	-$50M	-$62M	+18.3%